Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

800
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
800
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

540
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
540

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Authorship and citation trends in dementia research: A path to equitable career development for scientists.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Predicting the timing of first sustained cognitive worsening in Alzheimer's disease using real-world clinical data and machine learning.

medRxiv : the preprint server for health sciences·2026
Same author

Intraindividual cognitive variability predicts amyloid beta, tau PET, and dementia conversion in Down syndrome: a potential marker of cognitive resilience.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Promoting Research Excellence in Down Syndrome: Proceedings of the 5th International Conference of the Trisomy 21 Research Society.

Neuromolecular medicine·2026
Same author

Diabetes, impaired fasting glucose, and cognitive trajectories: a multi-cohort study.

medRxiv : the preprint server for health sciences·2026
Same author

CNS-selective plasma p-tau217 accurately captures Alzheimer's disease pathology and progression.

medRxiv : the preprint server for health sciences·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Correlates and predictors of self-efficacy among dementia caregivers: D-CARE findings.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

What should convince a clinician of disease modification in Alzheimer's disease clinical trials?

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Primary cilia-extracellular vesicle crosstalk in Alzheimer's disease: Emerging mechanisms and biomarker potential.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 17, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.2K

生物标志物 生物标志物

Xuemei Zeng1, Rebecca A Deek2, Michel N Nafash1

  • 1University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|January 14, 2026
PubMed
概括
此摘要是机器生成的。

像p-tau217这样的等离子体生物标志物显示出预测阿尔茨海默病 (AD) 和与AD相关的痴呆症 (ADRD) 的认知衰退的强大潜力. 这些血液检查可以识别有风险的个体,帮助早期诊断和个性化治疗策略.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

749

相关实验视频

Last Updated: Jan 17, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.2K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

749

科学领域:

  • 神经学 神经学
  • 生物标志物研究 生物标志物研究
  • 老年学是一门学科.

背景情况:

  • 血生物标志物在检测阿尔茨海默病 (AD) 和与AD相关的痴呆症 (ADRD) 脑病理方面表现有前途.
  • 血生物标志物与纵向认知衰退之间的确切关系尚不清楚.
  • 为了研究这种关系,使用了大量纵向数据的大型记忆诊所队列.

研究的目的:

  • 检查基线血生物标志物对近三十年认知衰退的预测价值.
  • 为了比较不同等离子体生物标志物 (p-tau181,p-tau217,BD-tau,GFAP,NfL) 在预测认知衰退方面的疗效.
  • 评估这些生物标志物的实用性,以识别面临认知衰退风险的个体,包括最初没有痴呆症的人.

主要方法:

  • 从匹兹堡大学阿尔茨海默氏病研究中心招募了参与者.
  • 收集血液样本并进行认知评估 (临床痴呆症评分 (CDR) 盒子总和) 截面和每年长达29年.
  • 使用SIMOA测定测量了p-tau181,p-tau217,BD-tau,GFAP和NfL的血水平;使用线性/逻辑回归和费舍尔的精确测试进行分析.

主要成果:

  • 所有测量的等离子体生物标志物的较高水平与认知功能 (CDR评分) 的较差相关.
  • 血p-tau181和GFAP最好地预测了不同时间间隔 (0-2,2-5,5-10,>10年) 的认知衰退率.
  • 血p-tau217表现出在2,5或10年内预测认知衰退发生的优越能力 (AUC高达0.810),特别是在没有基线痴呆症的个体中. 认知稳定的个体与进展的人相比,生物标志物水平较低.

结论:

  • 血生物标志物,特别是p-tau217,是预测患有AD/ADRD风险的个体认知衰退的有价值工具.
  • 这些基于血液的标志物可以识别逐渐发展到痴呆症的个体,即使从认知上正常的状态.
  • 这些发现支持使用血生物标志物进行个性化临床管理,改善神经退行性疾病患者的治疗结果.